← All trials
NCT06953453
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 23, 2025
- Primary completion
- Jul 20, 2026
- Completion date
- Aug 20, 2026
- First posted
- May 1, 2025
- Last posted
- Sep 25, 2025
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Lee's PharmaceuticalLead sponsor
- Jiao Tong UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.